Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Edwards Lifesciences (EWL) Stock Price & Analysis

EWL Stock Chart & Stats

€83.50-€1.32(-1.56%)
At close: 5:30 PM GMT+1
EUR 75EUR 803 Aug17 Aug31 Aug14 Sep28 Sep12 Oct27 Oct
Day’s Range
EUR 83.50 - EUR 85.00
52-Week Range
EUR 63.38 - EUR 85.00
Previous Close
EUR 84.82
Volume
807
Average Volume (3M)
43
Market Cap
EUR 47.33B
Enterprise Value
EUR 48.81B
Total Cash (Recent Filing)
EUR 4.25B
Total Debt (Recent Filing)
EUR 704.40M
Price to Earnings (P/E)
52.9
Beta
0.41
Next Earnings
Nov 04, 2026 (Est.)
EPS Estimate
0.66
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High Margins & Profitability

Sustained gross margins near the high 70s and a ~21% EBIT margin indicate durable pricing power and strong product mix in implantable devices and consumables. This margin base supports reinvestment in R&D and commercialization while cushioning cyclical procedure volume swings over years.

Very Strong Balance Sheet

Extremely low leverage and nearly $3B in cash give Edwards financial flexibility for share buybacks, targeted M&A, or elevated R&D spend without stressing liquidity. This buffer supports multi-year product launches and weathering reimbursement or procedure-volume variability.

Expanding Product Pipeline & TMTT

Rapid TMTT growth and multiple regulatory/clinical milestones diversify revenue beyond TAVR. New device approvals and strong durability data expand addressable markets (mitral/tricuspid and surgical), underpinning a multi-year structural growth runway and reducing single-product concentration risk.

Bears Say

Uneven Revenue & Cash Volatility

A history of revenue dips and variable operating/free cash flow signals sensitivity to procedure volumes, hospital purchasing cycles and working-capital timing. That variability complicates long-range planning for capex, buybacks and R&D allocation, raising execution risk through cycles.

Reimbursement & Trial Outcome Risk

Medicare coverage decisions and pivotal trial outcomes materially affect the addressable patient pool for TAVR/TMTT. Delay or unfavorable results would slow adoption, limit procedure volumes and constrain long-term revenue growth, making policy and clinical readouts structural growth levers.

Rising SG&A And Tax/Gaap Pressure

Increased SG&A spending reduces operating leverage and could compress margins if revenue ramps slower than planned. Higher effective tax and limits on R&D credits depress GAAP profitability, reducing retained earnings and free cash flow available for strategic initiatives over multiple years.

Edwards Lifesciences News

EWL FAQ

What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was €63.38 and its highest was €85.00 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is €47.33B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s next earnings report is estimated for Nov 04, 2026 (not yet confirmed), which is in 3 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Jul 23, 2026. The company reported €0.701 earnings per share for the quarter, beating the consensus estimate of €0.668 by €0.033.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.66.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 576,400,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of €0.701 in its last earnings report, beating expectations of €0.668. Following the earnings report the stock price went up 1.297%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Hedge funds hold Edwards Lifesciences shares: the largest hedge-fund position in Edwards Lifesciences is 2,068,114,160 shares, and hedge funds decreased their holdings by 1.3M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology